Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
64
THNR Quote, Financials, Valuation and Earnings
Last price:
$24.90
Seasonality move
:
-0.66%
Day range:
$25.22 - $25.25
52-week range:
$18.56 - $26.27
Dividend yield:
0.87%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
652
Avg. volume:
1.4K
1-year change:
4.4%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$25.22 | -- | -- | -- | $0.22 | 0.87% | -- |
|
AGNG
Global X Aging Population ETF
|
$36.31 | -- | -- | -- | $0.14 | 0.79% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$58.01 | -- | -- | -- | $0.33 | 4.86% | -- |
|
PPH
VanEck Pharmaceutical ETF
|
$99.61 | -- | -- | -- | $0.39 | 1.94% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.787 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.484 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.523 | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.233 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
Amplify Weight Loss Drug & Treatment ETF vs. Competitors
-
Which has Higher Returns THNR or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Global X Aging Population ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is THNR or AGNG More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.722%.
-
Which is a Better Dividend Stock THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0.87%. Global X Aging Population ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $0.14 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns THNR or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About THNR or JDOC?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is THNR or JDOC More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or JDOC?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0.87%. JPMorgan Healthcare Leaders ETF offers a yield of 4.86% to investors and pays a quarterly dividend of $0.33 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or JDOC?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
-
Which has Higher Returns THNR or PPH?
VanEck Pharmaceutical ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat VanEck Pharmaceutical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- PPHVanEck Pharmaceutical ETF-- -- -- -
What do Analysts Say About THNR or PPH?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Pharmaceutical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than VanEck Pharmaceutical ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than VanEck Pharmaceutical ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 PPHVanEck Pharmaceutical ETF0 0 0 -
Is THNR or PPH More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VanEck Pharmaceutical ETF has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.102%.
-
Which is a Better Dividend Stock THNR or PPH?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0.87%. VanEck Pharmaceutical ETF offers a yield of 1.94% to investors and pays a quarterly dividend of $0.39 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. VanEck Pharmaceutical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or PPH?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than VanEck Pharmaceutical ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than VanEck Pharmaceutical ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while VanEck Pharmaceutical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for VanEck Pharmaceutical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- PPHVanEck Pharmaceutical ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 62.68% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.8% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.82% over the past day.
